Journal
JOURNAL OF AFFECTIVE DISORDERS
Volume 172, Issue -, Pages 307-311Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jad.2014.09.015
Keywords
Ketamine; Bipolar depression; Shank3; MRI; PET
Categories
Funding
- National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH)
Ask authors/readers for more resources
Background: Shank3, a post-synaptic density protein involved in N-methyl-D-aspartate (NMDA) receptor tethering and dendritic spine rearrangement, is implicated in the pathophysiology of bipolar disorder. We hypothesized that elevated baseline plasma Shank3 levels might predict antidepressant response to the NMDA receptor antagonist ketamine. Methods: Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRl and 17 completed post-ketamine [F-18]-FDG PET. Results: Higher baseline Shank3 levels predicted antidepressant response at Days 1 (r=.39, p=.047), 2 (r=-.45, p=.02), and 3 (r=-.42, p=.03) and were associated with larger average (r =.58, p=.02) and right amygdala volume (r=.65, p=.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus (r=.51, p=.04) and amygdala (r=.58, p=.02). Limitations: Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging. Conclusions: Shank3 is a potential biomarker of antidepressant response to ketamine that correlates with baseline amygdala volume and increased glucose metabolism in the amygdala and hippocampus. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available